ArticleCureus2026
Correlation of Histopathological Parameters With Molecular Markers in Carcinoma Endometrium.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the association between molecular markers and histopathological parameters in endometrial carcinoma (EC).
methodsThis retrospective study was conducted at the Max Institute of Cancer Care, New Delhi, India, from January 2022 to May 2025, and included a total of 160 patients with EC. Molecular subtypes were determined using immunohistochemistry (IHC) for p53, mismatch repair (MMR) proteins, and POLE mutation status, and classified as "no specific molecular profile" (NSMP) where applicable. Histopathological variables, including histological subtype, tumor grade, stage, depth of myometrial invasion, lymphovascular space invasion (LVSI), and lymph node status, were evaluated for association with molecular subtypes using chi-square statistical analysis.
resultsSignificant associations were observed between molecular subtypes and both histological type and LVSI. A strong correlation was noted between histopathological parameters and tumor grade (p<0.0001). However, no significant association was found between molecular subtypes and disease stage (p=0.136). POLE mutations were rare, identified in only 0.6% of cases.
conclusionsImmunohistochemical markers based on The Cancer Genome Atlas (TCGA) classification show a strong correlation with established histopathological risk factors. Integrating molecular profiling into the routine diagnostic workup may improve prognostication and support personalized treatment strategies in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.